Search Results
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
Search for other papers by Kyungmin Lee in
Google Scholar
PubMed
Search for other papers by Sang-Hyun Lee in
Google Scholar
PubMed
Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science & Technology, Daejeon, Republic of Korea
Search for other papers by Wooil Kim in
Google Scholar
PubMed
Search for other papers by Jangwook Lee in
Google Scholar
PubMed
Search for other papers by Jong-Gil Park in
Google Scholar
PubMed
Search for other papers by Jang-Seong Kim in
Google Scholar
PubMed
Search for other papers by Jung Tae Kim in
Google Scholar
PubMed
Search for other papers by Yea Eun Kang in
Google Scholar
PubMed
Search for other papers by Minho Shong in
Google Scholar
PubMed
Search for other papers by Hyo Jin Lee in
Google Scholar
PubMed
Search for other papers by Jin-Man Kim in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
Search for other papers by Bon Seok Koo in
Google Scholar
PubMed
Daejeon Endo Internal Medicine, Daejeon, Republic of Korea
Search for other papers by Koon Soon Kim in
Google Scholar
PubMed
Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science & Technology, Daejeon, Republic of Korea
Search for other papers by Jeong-Ki Min in
Google Scholar
PubMed
potential of tyrosine kinase inhibitors in the treatment of ATC with low Dsg2 expression levels by targeting hepatocyte growth factor receptor (HGFR, c-MET). Materials and methods Patients and tissue specimens We retrospectively selected 10 ATC
Search for other papers by Gina Chia-Yi Chu in
Google Scholar
PubMed
Search for other papers by Haiyen E Zhau in
Google Scholar
PubMed
Search for other papers by Ruoxiang Wang in
Google Scholar
PubMed
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Search for other papers by André Rogatko in
Google Scholar
PubMed
Search for other papers by Xu Feng in
Google Scholar
PubMed
Search for other papers by Majd Zayzafoon in
Google Scholar
PubMed
Search for other papers by Youhua Liu in
Google Scholar
PubMed
Search for other papers by Mary C Farach-Carson in
Google Scholar
PubMed
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Search for other papers by Sungyong You in
Google Scholar
PubMed
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Search for other papers by Jayoung Kim in
Google Scholar
PubMed
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Search for other papers by Michael R Freeman in
Google Scholar
PubMed
Uro-Oncology Research, Surgery, Biomedical Sciences, Biostatistics and Bioinformatics Center, Department of Pathology, Department of Pathology, Department of Biochemistry and Cell Biology, Department of Medicine, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8750 Beverly Blvd., Atrium 103, Los Angeles, California 90048, USA Departments of
Search for other papers by Leland W K Chung in
Google Scholar
PubMed
bone and soft tissue homing ( Josson et al . 2011 ). These findings support an important role for RANKL–RANK signaling in PCa metastasis. Hepatocyte growth factor (HGF) and its receptor tyrosine kinase c-Met mediate cell motility, migration, increased
Search for other papers by Stephen Hiscox in
Google Scholar
PubMed
Search for other papers by Nicola J Jordan in
Google Scholar
PubMed
Search for other papers by Wen Jiang in
Google Scholar
PubMed
Search for other papers by Maureen Harper in
Google Scholar
PubMed
Search for other papers by Richard McClelland in
Google Scholar
PubMed
Search for other papers by Chris Smith in
Google Scholar
PubMed
Search for other papers by Robert I Nicholson in
Google Scholar
PubMed
/SF) is a multifunctional cytokine produced by stromal cells and exerts its effects in a paracrine fashion, through activation of the c-Met receptor protein, which is frequently expressed on the cells of epithelial origin ( Comoglio & Trusolino 2002
Search for other papers by Ralph Blumhardt in
Google Scholar
PubMed
University of Texas Health Science Center at San Antonio, San Antonio Military Medical Center, Tennessee Valley VA Healthcare System, Vanderbilt University Medical Center, UAMS Thyroid Center, San Antonio, Texas, USA
Search for other papers by Ely A Wolin in
Google Scholar
PubMed
Search for other papers by William T Phillips in
Google Scholar
PubMed
Search for other papers by Umber A Salman in
Google Scholar
PubMed
University of Texas Health Science Center at San Antonio, San Antonio Military Medical Center, Tennessee Valley VA Healthcare System, Vanderbilt University Medical Center, UAMS Thyroid Center, San Antonio, Texas, USA
Search for other papers by Ronald C Walker in
Google Scholar
PubMed
Search for other papers by Brendan C Stack Jr in
Google Scholar
PubMed
Search for other papers by Darlene Metter in
Google Scholar
PubMed
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy and the fifth most common cancer in women. DTC therapy requires a multimodal approach, including surgery, which is beyond the scope of this paper. However, for over 50 years, the post-operative management of the DTC post-thyroidectomy patient has included radioactive iodine (RAI) ablation and/or therapy. Before 2000, a typical RAI post-operative dose recommendation was 100 mCi for remnant ablation, 150 mCi for locoregional nodal disease, and 175–200 mCi for distant metastases. Recent recommendations have been made to decrease the dose in order to limit the perceived adverse effects of RAI including salivary gland dysfunction and inducing secondary primary malignancies. A significant controversy has thus arisen regarding the use of RAI, particularly in the management of the low-risk DTC patient. This debate includes the definition of the low-risk patient, RAI dose selection, and whether or not RAI is needed in all patients. To allow the reader to form an opinion regarding post-operative RAI therapy in DTC, a literature review of the risks and benefits is presented.
Search for other papers by Elke Tatjana Aristizabal Prada in
Google Scholar
PubMed
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Search for other papers by Julian Maurer in
Google Scholar
PubMed
Search for other papers by Michael Lauseker in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Heidelberg, Germany
German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Eva Jolanthe Koziolek in
Google Scholar
PubMed
Search for other papers by Jörg Schrader in
Google Scholar
PubMed
Royal Free Hospital ENETS Centre of Excellence, London, UK
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
Search for other papers by Karel Pacak in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zurich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
Search for other papers by Christoph Joseph Auernhammer in
Google Scholar
PubMed
Search for other papers by Svenja Nölting in
Google Scholar
PubMed
in both resistant cell lines, compared to the sensitive control cell line ( P < 0.01). Everolimus resistance increased migration potential and baseline c-Met activation The migration assay reflected a significant increase in the
Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Metal Targeted Therapy & Immunology lab, Childrens’ cancer institute, Sydney, NSW, Australia
Search for other papers by Riccardo Cazzoli in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Giuseppina De Petro in
Google Scholar
PubMed
Search for other papers by Germano Gaudenzi in
Google Scholar
PubMed
Search for other papers by Silvia Carra in
Google Scholar
PubMed
Search for other papers by Mauro Romanenghi in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Ilaria Grossi in
Google Scholar
PubMed
Search for other papers by Isabella Pallavicini in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Search for other papers by Saverio Minucci in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
enhancing the hypoxia pathway and subsequently the mesenchymal–epithelial transition (MET) ( Rapisarda et al. 2009 , Villaume et al. 2010 ). The upregulation of mesenchymal–epithelial transition factor (c-MET), which is known to be involved in the
Search for other papers by David J Gross in
Google Scholar
PubMed
Search for other papers by Gabriel Munter in
Google Scholar
PubMed
Search for other papers by Menachem Bitan in
Google Scholar
PubMed
Search for other papers by Tali Siegal in
Google Scholar
PubMed
Search for other papers by Alberto Gabizon in
Google Scholar
PubMed
Search for other papers by Ronny Weitzen in
Google Scholar
PubMed
Search for other papers by Ofer Merimsky in
Google Scholar
PubMed
Search for other papers by Aliza Ackerstein in
Google Scholar
PubMed
Search for other papers by Asher Salmon in
Google Scholar
PubMed
Search for other papers by Avishai Sella in
Google Scholar
PubMed
Search for other papers by Shimon Slavin in
Google Scholar
PubMed
( Adams et al. 2002 ). However, it has recently been shown that tumor oxygen deprivation can be a double-edged sword, since hypoxia induced signaling via the c -Met in tumor cells can result in a more aggressive tumor phenotype ( Bottaro & Liotta 2003
Search for other papers by Christina M Knippler in
Google Scholar
PubMed
Search for other papers by Motoyasu Saji in
Google Scholar
PubMed
Search for other papers by Neel Rajan in
Google Scholar
PubMed
Search for other papers by Kyle Porter in
Google Scholar
PubMed
Search for other papers by Krista M D La Perle in
Google Scholar
PubMed
Search for other papers by Matthew D Ringel in
Google Scholar
PubMed
al. 2013 ), upregulation of c-MET ( Byeon et al. 2016 , 2017 , Knauf et al. 2018 ) and acquired mutations in RAS genes ( Ofir Dovrat et al. 2018 ). Group I PAKs are a family of kinases that are activated by the small Rho GTPases, RAC1 and
Search for other papers by Camilo Jimenez in
Google Scholar
PubMed
Search for other papers by Sasan Fazeli in
Google Scholar
PubMed
Department of Endocrinology, Hospital Universitario San Vicente Fundacion, Medellin, Colombia
Search for other papers by Alejandro Román-Gonzalez in
Google Scholar
PubMed
-2 VEGFR-3 PDGFR-β RET c-MET FGFR1 Axitinib 1.2 0.25 0.29 1.6 - - - Cabozantinib - 0.035 - - 4 1.3 - Lenvatinib 22 4 5.2 39 - - 46 Pazopanib 10 30 47 84
Search for other papers by Jennifer A Woyach in
Google Scholar
PubMed
Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210, USA
Search for other papers by Manisha H Shah in
Google Scholar
PubMed
tyrosine kinase that has gained interest in thyroid cancer in addition to other malignancies is c-Met, a proto-oncogene that is the high-affinity receptor for hepatocyte growth factor and is important for regulation of cell migration, proliferation